Massachusetts

Psychedelic trials in Massachusetts

54 registered trials has a study site in Massachusetts, and 8 are recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With DepressionNCT05450432 · Massachusetts General Hospital	Recruiting	Phase 4	ketamine	1
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderNCT06247839 · Sharmin Ghaznavi	Recruiting	Phase 3	psilocybin	1
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
Psilocybin in Cancer Pain StudyNCT06001749 · Yvan Beaussant, MD, MSci	Recruiting	Phase 2	psilocybin	1
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With DepressionNCT06597695 · Juliana Zambrano, MD, MPH	Recruiting	Phase 1 / Phase 2	ketamine	1
Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsNCT07516405 · University of Colorado, Denver	Recruiting	Phase 1	psilocybin	6
MDMA-assisted Therapy for FibromyalgiaNCT06066853 · Spaulding Rehabilitation Hospital	Recruiting	Early Phase 1	mdma	1
Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant DepressionNCT07563868 · Massachusetts General Hospital	Recruiting	Not applicable	ketamine	2

Facilities

Where the research happens in Massachusetts

Facility	City	Trials
Massachusetts General Hospital	Boston	11
McLean Hospital	Belmont	6
Adams Clinical Boston	Boston	5
Adams Clinical	Watertown	5
Trauma Research Foundation	Boston	4
University of Massachusetts Medical School	Worcester	3
Athinoula A. Martinos Center for Biomedical Imaging	Charlestown	2
Adams Clinical Watertown	Boston	2
Dana-Farber Cancer Institute	Boston	2
Brigham and Women's Hospital	Boston	2
Depression Clinical and Reseach Program - MGH	Boston	2
Vitalix Clinical	Worcester	1
Massachusetts General Hospital, Chelsea	Chelsea	1
Massachusetts General Hospital's Depression and Clinical Research program	Boston	1
Copley Clinical	Boston	1
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA	Boston	1
Massachusetts General Hospital, Depression Clinical and Research Program	Boston	1
Elixia Health	Springfield	1
Harvard Medical School - McLean Hospital	Belmont	1
Adams Clinical - Boston (Copley Clinical)	Boston	1
Adams Clinical - Boston	Watertown	1
SISU	Springfield	1
Care Dimensions	Danvers	1
Clinical Site 103	Boston	1
Clinical Site 121	Boston	1
Elixia MA, LLC	Springfield	1
Brigham and Women's Faulkner Hospital	Boston	1
Massachusetts General Hosipital	Boston	1
Clinical Research Site	Boston	1
Beth Israel Deaconess Medical Center	Boston	1
Depression Clinical and Research Program - MGH	Boston	1

Stay told

When a trial opens in Massachusetts

All trials

Every trial with a Massachusetts site

Trial	Status	Phase	Substance	Sites
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With DepressionNCT05450432 · Massachusetts General Hospital	Recruiting	Phase 4	ketamine	1
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderNCT06247839 · Sharmin Ghaznavi	Recruiting	Phase 3	psilocybin	1
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
Psilocybin in Cancer Pain StudyNCT06001749 · Yvan Beaussant, MD, MSci	Recruiting	Phase 2	psilocybin	1
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With DepressionNCT06597695 · Juliana Zambrano, MD, MPH	Recruiting	Phase 1 / Phase 2	ketamine	1
Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsNCT07516405 · University of Colorado, Denver	Recruiting	Phase 1	psilocybin	6
MDMA-assisted Therapy for FibromyalgiaNCT06066853 · Spaulding Rehabilitation Hospital	Recruiting	Early Phase 1	mdma	1
Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant DepressionNCT07563868 · Massachusetts General Hospital	Recruiting	Not applicable	ketamine	2
Comparative Effectiveness of ECT vs. KETAMINE Over the LifespanNCT06034821 · Brigham and Women's Hospital	Enrolling by invitation	Phase 4	ketamine	10
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLC	Completed	Phase 4	ketamine	54
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)NCT03149991 · Massachusetts General Hospital	Completed	Phase 4	ketamine	6
Ketamine for Depression: An MRI StudyNCT02544607 · Massachusetts General Hospital	Completed	Phase 4	ketamine	1
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major DepressionNCT01260649 · Massachusetts General Hospital	Terminated	Phase 4	ketamine	1
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL Limited	Active, not recruiting	Phase 3	psilocybin	45
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS Pathways	Completed	Phase 3	psilocybin	40
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940 · COMPASS Pathways	Active, not recruiting	Phase 3	psilocybin	116
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)NCT06809595 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	36
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	22
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	34
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)NCT03537014 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	15
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)NCT04077437 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	14
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSDNCT04714359 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	15
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	90
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02418585 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	48
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionNCT02422186 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	69
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionNCT02497287 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	109
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT03434041 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	30
The Impact of Ketamine on the Reward Circuitry of Suicidal PatientsNCT02532153 · Massachusetts General Hospital	Withdrawn	Phase 3	ketamine	1
MDMA-AT for PTSD in Young Adults With Childhood TraumaNCT07765693 · Jenna M. Traynor	Not yet recruiting	Phase 2	mdma	1
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use DisorderNCT07296094 · Brigham and Women's Hospital	Not yet recruiting	Phase 2	psilocybin	1
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsNCT05407064 · Definium Therapeutics US, Inc.	Completed	Phase 2	lsd	22
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice CareNCT04950608 · Yvan Beaussant, MD, MSci	Completed	Phase 2	psilocybin	1
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)NCT06206265 · TRYP Therapeutics	Active, not recruiting	Phase 2	psilocybin	1
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	46
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderNCT05733546 · COMPASS Pathways	Active, not recruiting	Phase 2	psilocybin	5
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSDNCT03282123 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	12
Ketamine for OUD and Suicidal Ideation in the EDNCT06111339 · Brigham and Women's Hospital	Terminated	Phase 2	ketamine	1
Ketamine for the Treatment for Alcohol Use Disorder in the EDNCT05661669 · Brigham and Women's Hospital	Withdrawn	Phase 2	ketamine	1
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDDNCT05381974 · Massachusetts General Hospital	Withdrawn	Phase 2	psilocybin	1
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)NCT01920555 · Massachusetts General Hospital	Completed	Phase 2	ketamine	6
MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage CancerNCT00252174 · Brigham and Women's Hospital	Terminated	Phase 2	mdma	1
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive DisorderNCT02234011 · Mclean Hospital	Terminated	Phase 2	ketamine	1
Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural ConnectomeNCT06698848 · Massachusetts General Hospital	Active, not recruiting	Phase 1	ketamine	1
Ketamine for Major Depressive DisorderNCT03721900 · Shenox Pharmaceuticals, LLC	Unknown status	Phase 1	ketamine	3
The Effects of Ketamine on Respiratory Stimulation and Transpulmonary PressuresNCT01969227 · Massachusetts General Hospital	Completed	Not applicable	ketamine	2
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant DepressionNCT04239963 · Mclean Hospital	Completed	N/A	ketamine	1
Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar DisorderNCT05209217 · Mclean Hospital	Unknown status	N/A	ketamine	1
Physiological and Cognitive Biomarkers for Ketamine's Antidepressant EffectsNCT02669043 · Massachusetts General Hospital	Terminated	Not applicable	ketamine	1
Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive DisorderNCT01613820 · Massachusetts General Hospital	Withdrawn	Not applicable	ketamine	1
Ketamine Infusion for Treatment-resistant Major Depressive DisorderNCT01582945 · Massachusetts General Hospital	Completed	Not applicable	ketamine	1
Ketamine Versus Placebo for Treatment Resistant Major Depressive DisorderNCT01667926 · Massachusetts General Hospital	Completed	Not applicable	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere